MetaCap

Black Diamond Therapeutics (BDTX) vs Zura Bio (ZURA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Black Diamond Therapeutics (BDTX) has outperformed Zura Bio (ZURA) over the past year, losing 65.5% versus a loss of 74.4%. Zura Bio is the larger company by market cap ($89.6 million vs $75.3 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BDTX-65.53%ZURA-74.37%
+102%+10%-83%
Nov 21, 20251 yearNov 20, 2026
BDTX-28.02%ZURA-96.84%
+301%+93%-116%
Mar 20, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BDTX versus ZURA key metrics
MetricBDTXZURA
Share price$1.31$0.9305
Market cap$75.28M$89.63M
1-day change-5.76%-2.30%
YTD return-46.09%-82.24%
1-year return-65.53%-74.37%
5-year return-79.30%—
EPS (TTM)$-0.77$-1.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$70.00M—
Net income (latest FY)$22.37M$-68.65M
Operating margin17.89%—
Net margin31.95%—
52-week high$3.97$7.44
52-week low$1.31$0.919
Distance from 52-week high-67.00%-87.49%
Analyst consensusnonestrong_buy
Avg. price target upside+663.36%+759.75%
Average volume697.70K4.47M
Shares outstanding57.47M96.33M
Employees2140
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Black Diamond Therapeutics

BDTX stock →

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 21 employees

About Zura Bio

ZURA stock →

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragment bispecific antibody engineered to bind and neutralize both IL-17A and BAFF within a single therapeutic molecule, which is in Phase 2 clinical trial development.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 40 employees

BDTX vs ZURA FAQ

Which is bigger, Black Diamond Therapeutics or Zura Bio?

Zura Bio (ZURA) is larger, with a market capitalization of $89.63M compared with $75.28M for Black Diamond Therapeutics (BDTX).

Which stock has performed better over the past year, BDTX or ZURA?

BDTX returned -65.53% over the past 12 months, compared with -74.37% for ZURA (price return, excluding dividends). Past performance does not predict future results.

Are Black Diamond Therapeutics and Zura Bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons